These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20955264)

  • 41. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
    Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
    Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
    Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
    Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
    Strum SB; Scholz MC
    JAMA Oncol; 2016 May; 2(5):686. PubMed ID: 27244678
    [No Abstract]   [Full Text] [Related]  

  • 44. Depression related to (neo)adjuvant hormonal therapy for prostate cancer.
    van Tol-Geerdink JJ; Leer JW; van Lin EN; Schimmel EC; Stalmeier PF
    Radiother Oncol; 2011 Feb; 98(2):203-6. PubMed ID: 21256610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
    Serretta V; Altieri V; Morgia G; Nicolosi F; De Grande G; Mazza R; Melloni D; Allegro R; Ferraù F; Gebbia V
    Clin Genitourin Cancer; 2012 Sep; 10(3):174-9. PubMed ID: 22502790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
    Akaza H
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    Boccardo F; Rubagotti A; Battaglia M; Di Tonno P; Selvaggi FP; Conti G; Comeri G; Bertaccini A; Martorana G; Galassi P; Zattoni F; Macchiarella A; Siragusa A; Muscas G; Durand F; Potenzoni D; Manganelli A; Ferraris V; Montefiore F
    J Clin Oncol; 2005 Feb; 23(4):808-15. PubMed ID: 15681525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 52. Interstitial pneumonitis following bicalutamide treatment for prostate cancer.
    McCaffrey JA; Scher HI
    J Urol; 1998 Jul; 160(1):131. PubMed ID: 9628626
    [No Abstract]   [Full Text] [Related]  

  • 53. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical onset of bicalutamide-induced liver injury.
    Yun GY; Kim SH; Kim SW; Joo JS; Kim JS; Lee ES; Lee BS; Kang SH; Moon HS; Sung JK; Lee HY; Kim KH
    World J Gastroenterol; 2016 Apr; 22(15):4062-5. PubMed ID: 27099451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of change to flutamide for prostate cancer patient who developed breast pain during bicalutamide treatment (BIP-F study)].
    Kitamura Y; Okuno H; Sakura Y; Manabe Y; Masuda N; Ito H; Mishina M; Taoka R; Terai A; Sugimoto M; Kakehi Y
    Hinyokika Kiyo; 2014 Jan; 60(1):17-23. PubMed ID: 24594768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC; Harris JP; Dawkins GP
    BJU Int; 2007 Feb; 99(2):243-4. PubMed ID: 17313420
    [No Abstract]   [Full Text] [Related]  

  • 59. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
    Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.